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1. INTRODUCTION {#cam41751-sec-0006}
===============

Large‐scale and population‐based disease epidemiology is critical to inform resource allocation and research prioritization. However, current evidence is scarce, particularly for lymphoid malignancies. Lymphoid malignancies encompass a group of cancers varying enormously from the morphology, histology, immuno‐phenotypes, genotypes, as well as the clinical features, treatment, and outcomes.[1](#cam41751-bib-0001){ref-type="ref"}, [2](#cam41751-bib-0002){ref-type="ref"}

Recently, more attention has been paid to evaluate the distribution of lymphoma subtypes and to compare their incidences and prevalences between East and West countries, which might help to shed some light on the intricate etiology and associated genetic or environmental risk factors of lymphoid malignancies. As stated in a previous research, the incidence rates of mature T/natural killer (NK)‐cell lymphoma and extranodal marginal zone B‐cell lymphoma of mucosa‐associated lymphoid tissue type (MALT) were higher in Asian populations than those in North America and Europe.[2](#cam41751-bib-0002){ref-type="ref"}, [3](#cam41751-bib-0003){ref-type="ref"} In contrast, the incidences of follicular lymphoma and chronic lymphocytic leukemia (CLL) were relatively lower in Asians.[2](#cam41751-bib-0002){ref-type="ref"}, [3](#cam41751-bib-0003){ref-type="ref"} The epidemiology of Epstein‐Barr virus (EBV) and human T‐lymphoblastic virus‐1 (HTLV‐1) around the world as well as several genetic factors might be the explanation of discrepancy in incidence between Asia and West.[4](#cam41751-bib-0004){ref-type="ref"}, [5](#cam41751-bib-0005){ref-type="ref"}

Although several studies have assessed the subtype‐specific incidence rates of lymphoid malignancies between Western and Asian countries,[6](#cam41751-bib-0006){ref-type="ref"}, [7](#cam41751-bib-0007){ref-type="ref"}, [8](#cam41751-bib-0008){ref-type="ref"}, [9](#cam41751-bib-0009){ref-type="ref"} many of them were limited to one‐center studies and did not represent the whole population. In addition, because Taiwan is a multiethnic society with Austronesian heritage, the genetic composition of a Taiwanese population might be different from that of a Japanese or a South Korean population to some extent. Therefore, our study aims to conduct an epidemiological study on lymphoid malignancies within the Taiwanese population using Taiwan Cancer Registry Database (TCRD) and to compare the data acquired from Taiwan with that from Japan and the United States[7](#cam41751-bib-0007){ref-type="ref"} in order to reveal complicated etiology of lymphoma.

2. MATERIALS AND METHODS {#cam41751-sec-0007}
========================

2.1. Data source {#cam41751-sec-0008}
----------------

We collected information of the newly diagnosed lymphoma cases between 2002 and 2012 from the TCRD. The TCRD is a population‐based cancer registry established and funded by the Ministry of Health and Welfare (MOHW) in 1979. A Cancer Registry Advisory Board was organized and responsible for standardizing the procedures, definitions of terminology, and coding of the reporting system for the registry. The TCRD covers cancer patients with all ages who have been admitted to or have gone to hospitals with more than 50 beds. With 98.4% completeness and 91.5% diagnoses confirmed with histological and/or cytological verification, the TCRD has been used as a tremendous tool to enhance the quality of cancer care.[10](#cam41751-bib-0010){ref-type="ref"}, [11](#cam41751-bib-0011){ref-type="ref"} All cancer types were coded in the TCRD based on the International Classification of Diseases for Oncology, the Third Edition (ICD‐O‐3)[12](#cam41751-bib-0012){ref-type="ref"} since 2002.

2.2. Ethical statement {#cam41751-sec-0009}
----------------------

The protocol of our study was approved by the Research Ethics Committee of National Taiwan University Hospital (registration number, 201604051W).

2.3. Study population {#cam41751-sec-0010}
---------------------

Patients with Hodgkin lymphoma (HL) and non‐Hodgkin lymphoma (NHL) were identified using the ICD‐O‐3 codes reported by registries. Those with NHL were further categorized into three major types (aggressive B‐cell lymphoid neoplasm, indolent B‐cell lymphoid neoplasms, and T/NK‐cell lymphoid neoplasm) and 13 frequently seen subtypes according to the 2008 WHO classification system,[1](#cam41751-bib-0001){ref-type="ref"}, [2](#cam41751-bib-0002){ref-type="ref"} including diffuse large B‐cell lymphoma (DLBCL), follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Burkitt lymphoma (BL), mantle cell lymphoma (MCL), marginal zone B‐cell lymphoma (MZBCL, including MALT), peripheral T‐cell lymphoma‐NOS (PTCL‐NOS), mycosis fungoides (MF), cutaneous T‐cell lymphoma (CTCL), anaplastic large T/null‐cell lymphoma (ALCL), angioimmunoblastic T‐cell lymphoma (AITL), NK/T‐cell lymphoma, nasal type (NK/TCL), and adult T‐cell leukemia/lymphoma (ATLL). The disease codes used in this study are presented in Table [1](#cam41751-tbl-0001){ref-type="table"}. Patients without pathologically confirmed or aged younger than 20 years at the diagnosis were excluded.

###### 

Disease coding of Hodgkin and non‐Hodgkin lymphoma

  Disease                                                             ICD‐O‐3 code
  ------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  Hodgkin lymphoma                                                    96503‐96673
  Non‐Hodgkin lymphoma                                                
  Aggressive B‐cell lymphoid neoplasm                                 96733/96793/96803/96843/96873/96883/97123/97353/97373/97383/98263
  Diffuse large B‐cell lymphoma (DLBCL)                               96803/96843/96883/97123/97353/97373/97383
  Burkitt lymphoma (BL)                                               96873/98263
  Mantle cell lymphoma (MCL)                                          96733
  Indolent B‐cell lymphoid neoplasm                                   95973/96713/96753/96893/96903/96913/96953/96983/96993/97613/98233
  Follicular lymphoma (FL)                                            95973/96753/96903/96913/96953/96983
  Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)   98233
  Marginal zone B‐cell lymphoma (MZBCL)                               96893/96993
  T/NK‐cell lymphoid neoplasm                                         97003‐97023/97053/97083/97093/97143/97163‐97193/97263/97293/98273/98313/98343/98373/99483
  Peripheral T‐cell lymphoma‐NOS (PTCL‐NOS)                           97023
  Mycosis fungoides (MF)                                              97003
  Cutaneous T‐cell lymphoma (CTCL)                                    97013/97093/97183/97263
  Anaplastic large T/null‐cell lymphoma (ALCL)                        97143
  Angioimmunoblastic T‐cell lymphoma (AITL)                           97053
  NK/T‐cell lymphoma, nasal type (NK/TCL)                             97193
  Adult T‐cell leukemia/lymphoma (ATLL)                               98273

NOS, not otherwise specified.
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2.4. Statistical analysis {#cam41751-sec-0011}
-------------------------

Number of incidence, median age of diagnosis, and sex ratio were calculated and reported annually for patients with HL as well as three major types and 13 subtypes of NHL during the 11 years of study period (from 2002 to 2012). Crude rates and age‐standardized rates (ASRs) adjusted by the 2000 world standard population as defined by the World Health Organization[13](#cam41751-bib-0013){ref-type="ref"} were both presented as cases per 100 000 persons. We further investigated the distribution (proportion) of both sexes among all subtypes and compared the age‐standardized rates with those reported in Japan and the United States. All data in this study were analyzed using SAS^®^ software, version 9.4 (SAS Institute, Cary, NC, USA).

3. RESULTS {#cam41751-sec-0012}
==========

3.1. Overall incidence {#cam41751-sec-0013}
----------------------

From 2002 to 2012, a total of 21 929 cases were diagnosed with four major types of lymphoma in Taiwan. The crude incidence rates and age‐standardized rates of four major types and most of the subtypes of lymphomas increased during the 11‐year study period (Figures [1](#cam41751-fig-0001){ref-type="fig"}, [2](#cam41751-fig-0002){ref-type="fig"} and [S1, S2](#cam41762-sup-0002){ref-type="supplementary-material"}). Among the four major types, aggressive B‐cell lymphoma (52.21%, N = 11 450) was consistently the most common lymphoma followed by indolent B‐cell lymphoma (25.24%, N = 5535) and T/NK‐cell lymphoid neoplasm (15.12%, N = 3315). It was noteworthy that the crude incidence rate of indolent B‐cell lymphoma had a more than twofold increase in 11 years (from 1.12 per 100 000 persons in 2002 to 2.39 per 100 000 persons in 2012). The detailed percentages of four major types of lymphoma are demonstrated annually in [Figure S3](#cam41762-sup-0002){ref-type="supplementary-material"}. Hodgkin lymphoma remained the least occurred lymphoma (7.43%, N = 1629) throughout the study period although we observed a slight increase in crude incidence rates from 0.57 in 2002 to 0.75 in 2012 (Figure [1](#cam41751-fig-0001){ref-type="fig"}).

![Crude incidence rates of four major types of lymphoma in Taiwan between the years 2002‐2012](CAM4-7-5820-g001){#cam41751-fig-0001}

![Age‐standardized rates (ASRs) and trends of four major types of lymphoma in Taiwan between 2002 and 2012](CAM4-7-5820-g002){#cam41751-fig-0002}

As for the 13 subtypes of NHL, DLBCL accounted for almost half of the lymphoma cases (44.18%, N = 9688) and occurred far more frequently than the following four frequently diagnosed subtypes, including FL (9.47%, N = 2076), MZBCL (9.14%, N = 2004), CLL/SLL (5.66%, N = 1241), and PTCL‐NOS (4.73%, N = 1038). The lowest incidence was seen in ATLL (0.17%, N = 38), and some of the figures regarding this category were unavailable due to insufficient number of patients diagnosed in the calendar year (Table [2](#cam41751-tbl-0002){ref-type="table"}).

###### 

Number of incident cases and age‐standardized rates (ASRs) of patients with HL, three major types and 13 subtypes of NHL in Taiwan between 2002 and 2012

  Disease                               Number of incidence/ASR   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012                                                                                                                                                      
  ------------------------------------- ------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  HL                                    Number of Incidence       81     47     128    76     53     129    84     46     130    69     47     116    88     52     140    84     63     147    86     62     148    92     84     176    104    69     173    105    63     168    101    73     174
  ASR                                   0.68                      0.42   0.55   0.66   0.45   0.56   0.72   0.41   0.57   0.57   0.40   0.49   0.74   0.44   0.59   0.69   0.56   0.62   0.71   0.54   0.63   0.72   0.71   0.71   0.86   0.57   0.72   0.83   0.56   0.69   0.80   0.64   0.71   
  NHL                                                                                                                                                                                                                                                                                             
  Aggressive B‐cell lymphoid neoplasm   Number of Incidence       427    360    787    471    359    830    496    385    881    547    387    934    539    421    960    575    442    1017   592    424    1016   659    555    1214   692    524    1216   695    576    1271   729    595    1324
  ASR                                   3.46                      3.04   3.25   3.80   2.98   3.40   3.85   3.08   3.47   4.22   2.99   3.60   3.97   3.16   3.57   4.16   3.15   3.66   4.20   2.95   3.57   4.60   3.80   4.15   4.70   3.41   4.05   4.59   3.66   4.11   4.76   3.56   4.15   
  DLBCL                                 Number of Incidence       364    305    669    395    322    717    407    326    733    443    338    781    450    364    814    470    393    863    492    373    865    548    479    1027   574    458    1032   564    507    1071   600    516    1116
  ASR                                   2.95                      2.58   2.76   3.14   2.66   2.91   3.11   2.58   2.85   3.37   2.59   2.98   3.26   2.71   3.00   3.35   2.80   3.07   3.44   2.57   2.99   3.81   3.15   3.48   3.79   2.98   3.38   3.68   3.18   3.42   3.84   3.02   3.42   
  BL                                    Number of Incidence       20     22     42     26     13     39     30     19     49     32     18     50     33     25     58     41     12     53     31     17     48     30     21     51     35     14     49     24     15     39     38     14     52
  ASR                                   0.17                      0.20   0.18   0.23   0.12   0.18   0.28   0.18   0.23   0.29   0.16   0.22   0.29   0.22   0.26   0.34   0.09   0.21   0.28   0.15   0.21   0.25   0.16   0.21   0.33   0.09   0.21   0.22   0.11   0.16   0.31   0.12   0.21   
  MCL                                   Number of Incidence       18     5      23     19     3      22     22     6      28     30     6      36     26     6      32     29     13     42     29     7      36     42     14     56     42     14     56     43     13     56     31     9      40
  ASR                                   0.14                      0.04   0.09   0.17   0.02   0.09   0.16   0.05   0.11   0.24   0.05   0.14   0.19   0.04   0.12   0.22   0.09   0.15   0.20   0.05   0.12   0.28   0.09   0.18   0.27   0.09   0.18   0.27   0.08   0.17   0.19   0.05   0.12   
  Indolent B‐cell lymphoid neoplasm     Number of Incidence       139    114    253    155    125    280    139    145    284    195    134    329    188    169    357    211    190    401    199    195    394    248    216    464    255    263    518    265    243    508    304    254    558
  ASR                                   1.15                      0.95   1.05   1.21   1.00   1.11   1.07   1.15   1.11   1.48   0.99   1.23   1.39   1.23   1.31   1.5    1.34   1.42   1.37   1.35   1.36   1.7    1.46   1.57   1.74   1.73   1.72   1.74   1.54   1.64   1.91   1.55   1.72   
  FL                                    Number of Incidence       68     50     118    90     68     158    80     64     144    104    70     174    102    81     183    100    93     193    94     83     177    116    93     209    108    123    231    124    116    240    136    113    249
  ASR                                   0.56                      0.41   0.48   0.70   0.54   0.62   0.62   0.51   0.57   0.77   0.51   0.64   0.74   0.59   0.66   0.72   0.67   0.70   0.66   0.57   0.62   0.80   0.62   0.71   0.74   0.80   0.77   0.81   0.74   0.77   0.85   0.69   0.77   
  CLL/SLL                               Number of Incidence       55     27     82     57     28     85     64     40     104    66     37     103    63     36     99     73     28     101    74     43     117    86     44     130    94     46     140    97     55     152    72     56     128
  ASR                                   0.45                      0.23   0.34   0.45   0.22   0.34   0.49   0.31   0.40   0.52   0.28   0.40   0.46   0.26   0.36   0.51   0.19   0.35   0.50   0.30   0.40   0.58   0.29   0.43   0.63   0.29   0.45   0.64   0.33   0.47   0.44   0.33   0.39   
  MZBCL                                 Number of Incidence       67     63     130    58     53     111    52     79     131    79     60     139    70     83     153    101    95     196    90     108    198    112    117    229    118    131    249    109    112    221    132    115    247
  ASR                                   0.55                      0.53   0.54   0.46   0.43   0.45   0.40   0.63   0.51   0.61   0.45   0.53   0.53   0.61   0.57   0.71   0.66   0.69   0.61   0.75   0.68   0.76   0.79   0.78   0.80   0.87   0.83   0.72   0.71   0.72   0.83   0.71   0.77   
  T/NK‐cell lymphoid neoplasm           Number of Incidence       140    97     237    171    80     251    151    95     246    177    83     260    201    101    302    181    100    281    230    124    354    230    122    352    220    118    338    197    118    315    225    154    379
  ASR                                   1.14                      0.82   0.99   1.39   0.68   1.04   1.20   0.77   0.99   1.37   0.67   1.02   1.56   0.77   1.16   1.39   0.77   1.08   1.72   0.89   1.30   1.66   0.91   1.28   1.6    0.85   1.22   1.38   0.87   1.11   1.6    1.03   1.31   
  PTCL‐NOS                              Number of Incidence       60     36     96     58     31     89     49     37     86     59     22     81     60     36     96     55     22     77     75     38     113    71     30     101    84     32     116    57     28     85     58     40     98
  ASR                                   0.49                      0.31   0.40   0.46   0.26   0.36   0.38   0.29   0.34   0.45   0.18   0.32   0.46   0.27   0.37   0.40   0.16   0.28   0.54   0.27   0.40   0.51   0.20   0.35   0.59   0.21   0.40   0.40   0.17   0.28   0.38   0.25   0.31   
  MF                                    Number of Incidence       9      6      15     \*     \*     13     11     4      15     10     5      15     19     4      23     \*     \*     14     12     9      21     16     12     28     11     10     21     11     15     26     16     14     30
  ASR                                   0.07                      0.05   0.06   \*     \*     0.05   0.08   0.03   0.06   0.07   0.04   0.06   0.15   0.03   0.09   \*     \*     0.06   0.09   0.07   0.08   0.12   0.09   0.10   0.08   0.07   0.07   0.07   0.11   0.09   0.12   0.10   0.11   
  CTCL                                  Number of Incidence       4      8      12     15     3      18     \*     \*     6      14     3      17     12     5      17     3      4      7      9      5      14     6      6      12     \*     \*     6      6      4      10     \*     \*     5
  ASR                                   0.03                      0.06   0.05   0.13   0.02   0.08   \*     \*     0.03   0.10   0.02   0.06   0.09   0.04   0.07   0.02   0.03   0.03   0.07   0.04   0.06   0.04   0.05   0.04   \*     \*     0.02   0.04   0.03   0.04   \*     \*     0.02   
  ALCL                                  Number of Incidence       21     9      30     31     14     45     22     20     42     23     16     39     28     13     41     27     12     39     30     16     46     31     14     45     21     10     31     16     6      22     23     14     37
  ASR                                   0.18                      0.08   0.13   0.25   0.13   0.19   0.19   0.17   0.18   0.20   0.14   0.17   0.23   0.11   0.17   0.22   0.10   0.16   0.24   0.12   0.18   0.23   0.11   0.17   0.16   0.09   0.13   0.12   0.06   0.09   0.18   0.13   0.15   
  AITL                                  Number of Incidence       9      11     20     16     11     27     19     9      28     18     5      23     16     11     27     28     15     43     19     14     33     29     20     49     26     18     44     29     12     41     26     26     52
  ASR                                   0.08                      0.09   0.08   0.12   0.09   0.11   0.15   0.07   0.11   0.14   0.03   0.09   0.13   0.08   0.10   0.21   0.10   0.16   0.13   0.09   0.11   0.20   0.13   0.16   0.18   0.12   0.15   0.19   0.08   0.13   0.17   0.15   0.16   
  NK/TCL, nasal type                    Number of Incidence       20     17     37     24     8      32     32     14     46     29     19     48     43     17     60     34     21     55     46     20     66     40     24     64     31     19     50     40     22     62     48     30     78
  ASR                                   0.16                      0.13   0.15   0.19   0.06   0.13   0.25   0.11   0.18   0.22   0.14   0.18   0.33   0.12   0.22   0.25   0.16   0.20   0.34   0.14   0.24   0.27   0.16   0.21   0.21   0.13   0.17   0.27   0.15   0.21   0.31   0.18   0.24   
  ATLL                                  Number of Incidence       \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     3      \*     \*     3      \*     \*     6      \*     \*     12     \*     \*     6
  ASR                                   \*                        \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     \*     0.01   \*     \*     0.01   \*     \*     0.02   \*     \*     0.04   \*     \*     0.02   

\*, Not available due to insufficient case numbers.
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3.2. Distribution of age and sex {#cam41751-sec-0014}
--------------------------------

NHL tended to occur at older ages than HL. Among NHL patients, the median age at diagnosis of aggressive B‐cell lymphoid neoplasm was the eldest (63.0‐65.0 years) followed by that of indolent B‐cell lymphoid neoplasm (56.0‐62.0 years) and then that of T/NK‐cell lymphoid neoplasm (54.0‐58.0 years) during 2002‐2012 (Figure [3](#cam41751-fig-0003){ref-type="fig"}). However, there was heterogeneity among the subtypes. Patients with BL (31.0‐56.0 years) and ALCL (37.0‐54.0 years) were younger at diagnosis than the other subtypes ([Figure S4](#cam41762-sup-0002){ref-type="supplementary-material"}). As for the sex distribution, the patients with T/NK‐cell lymphoid neoplasm were the most male predominant (sex ratio: 1.39‐2.07, [Figure S5](#cam41762-sup-0002){ref-type="supplementary-material"}). Detailed sex ratios of 13 subtypes revealed the male predominance in MCL (sex ratio: 2.18‐6.09) and CLL/SLL (sex ratio: 1.55‐2.55), compared with the sex ratios of aggressive B‐cell lymphoid neoplasm and indolent B‐cell lymphoid neoplasm, respectively ([Figure S6](#cam41762-sup-0002){ref-type="supplementary-material"}). The incidence trends concerning four major types of lymphoma during 2002 to 2012 increased gradually and were similar between men and women (Figure [4](#cam41751-fig-0004){ref-type="fig"}). Furthermore, the incidences of most lymphoma were higher in males than those in females, especially for aggressive B‐cell lymphoma (male: 3.46‐4.76 per 100 000; female: 2.95‐3.80 per 100 000) and T/NK‐cell lymphoma (male: 1.14‐1.72 per 100 000; female: 0.67‐1.03 per 100 000) in the four major types, and DLBCL (male: 2.95‐3.84 per 100 000; female: 2.57‐3.18 per 100 000) in the 13 subtypes (Table [2](#cam41751-tbl-0002){ref-type="table"}, Figures [4](#cam41751-fig-0004){ref-type="fig"} and [S7](#cam41762-sup-0002){ref-type="supplementary-material"}).

![Median age at diagnosis of patients with four major types of lymphoma in Taiwan between 2002 and 2012](CAM4-7-5820-g003){#cam41751-fig-0003}

![Incidence trends between men and women of four major types of lymphoma in Taiwan between 2002 and 2012 (A) Hodgkin lymphoma, (B) aggressive B‐cell lymphoid neoplasm, (C) indolent B‐cell lymphoid neoplasm, and (D) T/NK‐cell lymphoid neoplasm](CAM4-7-5820-g004){#cam41751-fig-0004}

3.3. International comparison {#cam41751-sec-0015}
-----------------------------

Comparisons of subtype‐specific incidence rates of lymphoid malignancies among the United States, Japan, and Taiwan are depicted in Figures [5](#cam41751-fig-0005){ref-type="fig"} and [S8](#cam41762-sup-0002){ref-type="supplementary-material"}, and detailed data are presented in [Table S1](#cam41762-sup-0002){ref-type="supplementary-material"}. Notably, during 2002 to 2008, the ASRs of Hodgkin lymphoma in Taiwan (male: 0.57‐0.74 per 100 000, female: 0.40‐0.56 per 100 000) were obviously lower than that in the United States (male: 2.72‐3.17 per 100 000, female: 2.17‐2.60 per 100 000) and comparable to that in Japan (male: 0.38‐0.59 per 100 000, female: 0.24‐0.47 per 100 000) in both sex. The ASRs of aggressive and indolent B‐cell lymphoid neoplasms were distinctly different among the United States, Taiwan, and Japan. In patients with DLBCL (Table [2](#cam41751-tbl-0002){ref-type="table"}, Figure [5](#cam41751-fig-0005){ref-type="fig"}A,B) and MZBCL (Table [2](#cam41751-tbl-0002){ref-type="table"}, Figure [5](#cam41751-fig-0005){ref-type="fig"}E,F), and in male patients with BL (Table [2](#cam41751-tbl-0002){ref-type="table"} and Figure [5](#cam41751-fig-0005){ref-type="fig"}C), the incidences were highest in the US population, lowest in the Japanese population, and intermediate in the Taiwanese population. In contrast, the ASRs were divergent in NK/TCL, nasal type (Table [2](#cam41751-tbl-0002){ref-type="table"}, Figure [5](#cam41751-fig-0005){ref-type="fig"}G,H). The ASRs of NK/TCL were highest in the Taiwanese population and lowest in the US population.

![Age‐standardized rates of DLBCL,BL,MZBCL, and NK/TCL, nasal type, in American, Japanese, and Taiwanese males and females between 2002 and 2008 (A) Diffuse large B‐cell lymphoma: male, (B) diffuse large B‐cell lymphoma: female, (C) Burkitt lymphoma: male, (D) Burkitt lymphoma: female, (E) marginal zone B‐cell lymphoma: male, (F) marginal zone B‐cell lymphoma: female, (G) NK/T‐cell lymphoma, nasal type: male, and (H) NK/T‐cell lymphoma, nasal type: female](CAM4-7-5820-g005){#cam41751-fig-0005}

4. DISCUSSION {#cam41751-sec-0016}
=============

To the best of our knowledge, this population‐based study is the largest and the most comprehensive epidemiologic study to provide information on subtype‐specific epidemiology of lymphoid malignancies in the Taiwanese population, and it shows the differences in incidences among Taiwan, Japan, and the United States. Our study has the merits of using the population‐based data, which fills the knowledge gap that many of the existing studies are limited to single‐center studies and thought to be unrepresentative.[8](#cam41751-bib-0008){ref-type="ref"}, [14](#cam41751-bib-0014){ref-type="ref"}, [15](#cam41751-bib-0015){ref-type="ref"} In addition, using the year 2000 world standard population for incidence, adjustment made us able to compare our findings to those in Japan and the United States from the previous studies.[7](#cam41751-bib-0007){ref-type="ref"}

In our study, the ratio of HL and NHL is consistent with the previous smaller‐scale study conducted in Taiwan.[8](#cam41751-bib-0008){ref-type="ref"} HL and NHL accounted for 6.09% and 93.32% of all lymphoid malignancies in the previous study,[8](#cam41751-bib-0008){ref-type="ref"} and our study obtained the similar results (HL, 7.9%; and NHL, 92.1%). Compared with studies from other countries, NHL tended to occur more frequently in both Eastern and Western countries although the percentages of HL are higher in Western countries.[7](#cam41751-bib-0007){ref-type="ref"}, [8](#cam41751-bib-0008){ref-type="ref"}, [14](#cam41751-bib-0014){ref-type="ref"}, [15](#cam41751-bib-0015){ref-type="ref"}, [16](#cam41751-bib-0016){ref-type="ref"}, [17](#cam41751-bib-0017){ref-type="ref"} In the United States and the United Kingdom (UK), HL constituted 9.96% and 14.41% of patients with lymphoid neoplasms.[16](#cam41751-bib-0016){ref-type="ref"}, [17](#cam41751-bib-0017){ref-type="ref"} In Eastern countries, by contrast, HL accounted for 4.12%, 5.9%, 8.60%, and 7.43% of patients with lymphoid neoplasms in South Korea, Japan, China, and Taiwan (our study), respectively.[7](#cam41751-bib-0007){ref-type="ref"}, [14](#cam41751-bib-0014){ref-type="ref"}, [15](#cam41751-bib-0015){ref-type="ref"}

Because NHL is composed of different types of lymphoma, we further make the comparisons between our results and the previously published one from other countries. B‐cell lymphoma (BCL) accounts for the majority of NHL in both Western and Eastern countries.[7](#cam41751-bib-0007){ref-type="ref"}, [8](#cam41751-bib-0008){ref-type="ref"}, [14](#cam41751-bib-0014){ref-type="ref"}, [15](#cam41751-bib-0015){ref-type="ref"}, [16](#cam41751-bib-0016){ref-type="ref"}, [17](#cam41751-bib-0017){ref-type="ref"} In the United States and UK, BCL composes of 93.37% and 93.79% of NHL cases, respectively.[16](#cam41751-bib-0016){ref-type="ref"}, [17](#cam41751-bib-0017){ref-type="ref"} However, the percentages of BCL are slightly lower and are 81.60%, 77.05%, 71.05%, and 83.67% of NHL patients in South Korea, Japan, China, and Taiwan (our study).[7](#cam41751-bib-0007){ref-type="ref"}, [14](#cam41751-bib-0014){ref-type="ref"}, [15](#cam41751-bib-0015){ref-type="ref"} In detail, the majority of BCL cases was DLBCL in both Eastern and Western countries, and the percentages were variable (38.92% in the United States,[18](#cam41751-bib-0018){ref-type="ref"} 43.24% in the UK,[17](#cam41751-bib-0017){ref-type="ref"} 45.8% in the Central and South America,[19](#cam41751-bib-0019){ref-type="ref"} 47.75% in South Korea,[15](#cam41751-bib-0015){ref-type="ref"} 62.48% in Japan,[7](#cam41751-bib-0007){ref-type="ref"} 55.78% in Mainland China,[14](#cam41751-bib-0014){ref-type="ref"} and 57.04% in Taiwan, our study). The second and third frequent types of BCL are FL and MZBCL in Japan and Taiwan (our study). FL and MZBCL accounted for 18.60% and 9.93% of BCL patients in Japan,[7](#cam41751-bib-0007){ref-type="ref"} and 12.22% and 11.80% in Taiwan. However, the percentage of FL is lower in Mainland China (4.48%)[14](#cam41751-bib-0014){ref-type="ref"} and South Korea (2.68%).[15](#cam41751-bib-0015){ref-type="ref"} Why the frequencies of FL differ among Asian countries remains uncertain. The previous study suggests several potential risk factors, such as diet modernization, inoculation rate of influenza vaccination, single nucleotide polymorphisms (SNPs) within the major histocompatibility complex (MHC) region, and environmental factors.[20](#cam41751-bib-0020){ref-type="ref"} Compared to our study, MZBCL (MALT included) in South Korea is the second majority of BCL, and it composed 19.45% of patients diagnosed with BCL.[15](#cam41751-bib-0015){ref-type="ref"} *Helicobacter pylori* infection is related to MALT, and *H. pylori* irradiation is the frontline treatment for the patients with limited stage MALT.[21](#cam41751-bib-0021){ref-type="ref"} Therefore, higher proportion of MZBCL in South Korea may be related to the high prevalence of *H. pylori* and endoscopy screening policy for gastric cancer.[22](#cam41751-bib-0022){ref-type="ref"}, [23](#cam41751-bib-0023){ref-type="ref"}

About T‐cell lymphoma (TCL), the incidence rates are higher in Eastern countries than those in Western countries.[7](#cam41751-bib-0007){ref-type="ref"}, [8](#cam41751-bib-0008){ref-type="ref"}, [14](#cam41751-bib-0014){ref-type="ref"}, [15](#cam41751-bib-0015){ref-type="ref"}, [16](#cam41751-bib-0016){ref-type="ref"}, [17](#cam41751-bib-0017){ref-type="ref"} In the United States and the UK, TCL accounts for 6.63% and 6.21% of NHL, respectively,[16](#cam41751-bib-0016){ref-type="ref"}, [17](#cam41751-bib-0017){ref-type="ref"} whereas the incidences of TCL in South Korea, Japan, Mainland China, and Taiwan (our study) are threefold to fourfold higher (17.16%, 19.98%, 28.95%, and 16.33% of NHL patients, respectively).[7](#cam41751-bib-0007){ref-type="ref"}, [14](#cam41751-bib-0014){ref-type="ref"}, [15](#cam41751-bib-0015){ref-type="ref"} Nevertheless, the frequencies of TCL subtypes vary among Asian countries. The most frequent type in Japan is ATLL (45.86% of TCL),[7](#cam41751-bib-0007){ref-type="ref"} but PTCL‐NOS in South Korea (31.6%) and Taiwan (31.31%),[15](#cam41751-bib-0015){ref-type="ref"} and NK/TCL in Mainland China (47.04%).[14](#cam41751-bib-0014){ref-type="ref"} In South Korea, NK/TCL is the second common TCL and constitutes 30.9% of TCL patients.[15](#cam41751-bib-0015){ref-type="ref"} The disparity in the distribution of TCL subtypes among countries may be attributable to different lifestyles, environmental factors, and genetic polymorphisms.[24](#cam41751-bib-0024){ref-type="ref"}, [25](#cam41751-bib-0025){ref-type="ref"} In addition, viral infections also play a pivotal role in TCL, such as EBV infections in NK/TCL, nasal type, and HTLV‐1 infections in ATLL. High prevalence of EBV infection in Asian countries and high HTLV‐1 carrier rate in south Japan contribute to the relatively high incidence of NK/TCL and ATLL in these area.[4](#cam41751-bib-0004){ref-type="ref"}, [5](#cam41751-bib-0005){ref-type="ref"} Unlike southern Japan, in which the HTLV‐1 prevalence was reported to be the highest in the world (more than 10%), the HTLV‐1 prevalence was reported to be between 0.1 and 1% in Taiwan.[26](#cam41751-bib-0026){ref-type="ref"} Another study also reported that the prevalence of HTLV‐1 in Japan was between 1 080 000 and 1 300 000/127 368 088 persons and that in Taiwan was between 10 000 and 30 000/23 113 901 persons.[27](#cam41751-bib-0027){ref-type="ref"} These may explain the differences of prevalence of ATLL in Japan and Taiwan.

In addition to disease incidences, we further compare age‐standardized rates (ASRs) of lymphoid malignancies in Taiwan with those in Japan and the United States, and all adjustments are made according to the 2000 world standard population as defined by the World Health Organization.[7](#cam41751-bib-0007){ref-type="ref"} In most lymphoid malignances, the ASRs are the highest in the United States followed by those in Taiwan and then in Japan, especially in HL, aggressive B‐cell lymphoma, and indolent B‐cell lymphoma. In TCL, however, except for MF, CTCL, and ALCL, ASRs in Taiwan were mostly the highest in PTCL‐NOS, NK/TCL, and AITL during 2002 to 2008. As for comparisons with Hong Kong (2001‐2010), South Korea (1999‐2012), and Surveillance, Epidemiology, and End Results Program (SEER) data in Asian Americans (2001‐2010), notably, the ASR of HL in Taiwan (0.49‐0.72 per 100 000 persons) was lower than that in SEER Asian Americans (1.28 per 100 000 persons) but comparable to that in Hong Kong (0.75 per 100 000 persons) and higher than that in South Korea (0.35 per 100 000 persons). And likewise, ASRs of BCL among SEER Asian Americans, Taiwan, Hong Kong, and South Korea, including DLBCL, FL, MCL, BL, and CLL/SLL, showed the same pattern, in which ASRs of SEER Asian Americans were the highest followed by those of Taiwan and Hong Kong, and then those of South Korea. As for TCL, ASR of PTCL‐NOS in Taiwan (0.28‐0.40 per 100 000 persons) was higher or comparable to that in SEER Asian Americans (0.28 per 100 000 persons), in Hong Kong (0.27 per 100 000 persons), and in South Korea (0.26 per 100 000 persons). For ASR of NK/TCL, that in Taiwan (0.13‐0.24 per 100 000 persons) was comparable to that in Hong Kong (0.25 per 100 000 persons) and in South Korea (0.22 per 100 000 persons), and was obviously higher than that in SEER Asian Americans (0.12 per 100 000 persons).[6](#cam41751-bib-0006){ref-type="ref"}, [9](#cam41751-bib-0009){ref-type="ref"} The differences in ASRs of lymphoid malignancies are not only observed between Eastern and Western countries but also among Asians living in diverse countries. This observation strengthens the assumption that the etiology of lymphoid malignancies consists of genetics, environmental factors, and lifestyles.

As for subtype‐specific sex ratio of lymphoid malignancies in Taiwan, male predominance is most obvious in MCL patients (sex ratio, 2.18‐6.09), which is consistent with the results found in Hong Kong and in the United States (standardized rate ratio (SRR) in Hong Kong, 4.3; incidence rate and rate ratio (IRR) in the United States, 3.07).[6](#cam41751-bib-0006){ref-type="ref"}, [28](#cam41751-bib-0028){ref-type="ref"} However, etiology of the male predominance in MCL still remains unclear. Interestingly, despite the male predominance noticed in most subtypes of lymphoma, no such phenomenon was observed in DLBCL (sex ratio, 1.11‐1.29), MZBCL (sex ratio, 0.64‐1.28), and FL (sex ratio, 0.87‐1.44). These findings are consistent with the results in Hong Kong, where SRRs of DLBCL, MZBCL, and FL were 1.3, 1.1, and 1.1, respectively.[6](#cam41751-bib-0006){ref-type="ref"} As for the United States, though IRRs of MZBCL (1.05) and FL (1.18) were the lowest among all subtypes as well, DLBCL was a bit more male‐predominated than Taiwan and Hong Kong instead with IRR of 1.49.[28](#cam41751-bib-0028){ref-type="ref"} Further research concerning subtype‐specific etiology of lymphoma is still urgently required to elucidate the sex difference.

While we provide tremendous epidemiologic information of lymphoma, the present study has some limitations. First, the incidence of some TCL in Taiwan was extremely low, such as MF, CTCL, and ATLL. Therefore, it should be very cautious when making comparisons with the incidences in other countries. Second, the subtype‐specific incidences of lymphoma in the South Korea population were adjusted according to Segi world population, which is different from the standard applied in our study.[9](#cam41751-bib-0009){ref-type="ref"} The slight discrepancies may therefore be arisen when we try to make the comparisons with the data in South Korea. Nevertheless, there are still merits of our study. Using population‐based data source, our results are representative enough of the Taiwanese population. Moreover, adjustments made on incidence rates according to the 2000 world standard population let us be able to evaluate the dissimilarity existing among countries. In this way, our data are worth helping unveil the rather mysterious etiology of lymphoma.

Conclusively, our study is the first population‐based study conducted in Taiwan aiming to investigate subtype‐specific epidemiology of lymphoma. Most of the incidence rates of lymphoid malignancies in Taiwan are lower than those in the United States, and higher than or comparable to those in Japan except that the ASRs of some TCL are the highest, including PTCL/NOS, AITL, and NK/TCL. The researches regarding the subtype‐specific epidemiology of lymphoid malignancies in different countries or regions are crucial to elucidate the etiologies of lymphoma. Further investigations about the subtype‐specific survival of lymphoid malignancies in Taiwan are required to clarify the natural history of lymphoma and the impact of ever‐advancing therapies.
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